JPRN-UMIN000023035
Completed
未知
Evaluation of the efficacy and safety of luseogliflozin and changes in QOL - Evaluation of the efficacy and safety of luseogliflozin and changes in QOL (Lusefi QOL study)
The Institute for Adult Diseases, Asahi Life Foundation0 sites64 target enrollmentJuly 11, 2016
ConditionsType 2 diabetes mellitus
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Type 2 diabetes mellitus
- Sponsor
- The Institute for Adult Diseases, Asahi Life Foundation
- Enrollment
- 64
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients with diabetes other than type 2 diabetes 2\) Patients with a history of cardiovascular events such as cerebral infarction and myocardial infarction. 3\) Patients with serious renal or hepatic dysfunction 4\) Patients with malignant tumors (those who have a history of malignant tumors but are currently receiving no treatment and had no recurrence, and those considered unlikely to have any recurrence during the study period are eligible for the study). 5\) Patients with repeated genital or urinary tract infections 6\) Patients with eGFR \<\=30 mL/min/1\.73 m2 7\) Patients with BMI \<\=20 8\) Patients for whom dosage and administration of concomitant antidiabetic drugs have been changed within the 12 weeks prior to the start of administration of the study drug. 9\) Patients who have administered a SGLT2 inhibitor within 6 months prior to the start of administration of the study drug 10\) Patients whose answers to the questionnaire at week 0 were not collected before the start of administration. 11\) Patients deemed unsuitable for participation in the study by the investigator or sub\-investigator due to other reasons.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Evaluation of the safety and efficacy in linagliptin with type 2 diabetic patients receiving hemodialysis therapytype 2 diabetes mellitusJPRN-UMIN000010099Saitama medical University50
Completed
Phase 4
The study to evaluate the efficacy and safety of linear high intensity focus ultrasound for enlarged pores in Thailand, Pilot studyHealthy human volunteersHigh intensity focused ultrasoundFaceSkinTCTR20220701006Dermatologic Surgery, Dermatology department, Siriraj hospital, Thailand30
Completed
Phase 4
The study to evaluate the efficacy and safety of linear high intensity focus ultrasound for lower face sagging in Thailand, A pilot studyHealthy human volunteersHigh intensity focused ultrasoundFaceSkinTCTR20220629011Dermatologic Surgery, Dermatology department, Siriraj hospital, Thailand30
Completed
Phase 4
The study to evaluate the efficacy and safety of linear high intensity focus ultrasound for upper face laxity in Thailand, Pilot studyHealthy human volunteersHigh intensity focused ultrasoundFaceSkinTCTR20220629009Dermatologic Surgery, Dermatology department, Siriraj hospital, Thailand30
Terminated
Phase 4
A Prospective Study on Efficacy and Safety of Filgrastim (Leuco-Plus 300) for Prevention of Chemotherapy Induced Neutropenia in Patients with Diffuse Large B-Cell LymphomaPatients with Diffuse Large B-Cell LymphomaDLBCLCHOPR-TCTR20170802002Apexcela Co., Ltd.20